San Antonio Company Develops A New Test For Lung Cancer

PUBLISHED ON August 24, 2017

Texas Public Radio (August 24, 2017 ) A new, more accurate, test for lung cancer is being developed in San Antonio. It’s a screening that could help save the lives of thousands of people who are often diagnosed too late to survive the disease.

read more

City of San Antonio Invests in bioAffinity Technologies

PUBLISHED ON March 9, 2017

SAN ANTONIO, TX (March 9, 2017) The San Antonio City Council today authorized the San Antonio Economic Development Corporation (SAEDC) to invest in locally based bioAffinity Technologies, a biotech company focused on the significant unmet need for non-invasive, early- stage cancer diagnostics and improved cancer treatments.

read more

bioAffinity Technologies is proud to play a part in the University of Texas Health video highlighting our impressive research collaboration to uncover the mechanisms of cancer. The collaboration with the University of Texas, a leader in innovation, has led to exciting advancements that further the development and commercialization of our life-saving tests and treatments for cancer. In this video, you’ll see physicians, scientists, and bioAffinity Technologies CEO Maria Zannes discuss how medical breakthroughs are being commercialized and made available to those who need them, including more about how we’re moving forward with our CyPath® diagnostic tests and OncoSelect® therapeutics.